Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 5/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24013365 | 0.86 | SIGMAR1 (0.43) | SIGMAR1BCHEIDO1CYP1A2CYP2D6 | |
| SCHEMBL7766011 | 0.85 | HRH3 (0.56) | HRH3BCHECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL20097366 | 0.80 | HRH3 (0.47) | HRH3BCHECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3718853 | 0.79 | ALDH1A1 (0.54) | HRH3SIGMAR1BCHEIDO1CYP1A2 | |
| SCHEMBL13181462 | 0.79 | HRH3 (0.50) | HRH3BCHECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL9885275 | 0.79 | HRH3 (0.50) | HRH3BCHECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13667480 | 0.78 | TSHR (0.62) | HRH3SIGMAR1BCHECYP1A2CYP2D6 | |
| SCHEMBL26686942 | 0.78 | TSHR (0.52) | HRH3BCHECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL12772084 | 0.78 | TAAR1 (0.48) | HRH3BCHEIDO1CYP1A2CYP2D6 | |
| SCHEMBL807255 | 0.77 | HSD17B10 (0.50) | SIGMAR1IDO1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803956-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803956-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803956-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100125073-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | US | disclosed |
| US-20100125073-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | US | disclosed |
| US-20100125073-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | US | disclosed |
| US-7659412-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659412-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659412-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-11-26 | — | — | US | disclosed |
| US-7351735-B2 | Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2008025509-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025509-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
| US-20060194816-A1 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAER PHAMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
| EP-1487813-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1654245-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050139814-A1 | Benzofuran and benzothiophene derivatives useful in the treatmint of hyper-proliferative disorders | BAYER HEALTHCARE LLC | 2005-06-30 | — | — | US | disclosed |
| WO-2005014566-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
| EP-1487813-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003072561-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | HRH3 2348/4885SIGMAR1 4162/4885BCHE 4727/4885 |
| US-20060194816-A1 | Benzofuran derivatives useful for treating hyper-proliferative disorders | MKI67, PCNA, CCNI | HRH3 2170/4885SIGMAR1 4255/4885BCHE 4720/4885 |
| US-20100125073-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BCOR, BRDT, TPMT | HRH3 3545/4885SIGMAR1 3759/4885BCHE 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.